文献速递慢性静脉疾病

华法林抗凝患者行射频或激光大/小隐静脉消融安全有效且持久

Radiofrequency and laser vein ablation for patients receiving warfarin anticoagulation is safe, effective, and durable.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-01-25

单中心回顾性研究比较华法林抗凝患者与未抗凝对照接受大/小隐静脉射频或激光消融的疗效与安全性。抗凝组100例手术、对照组127例手术,平均随访467天。1年靶血管持续消融率抗凝组96%、对照组99%,18个月为92%对95%(P = .96);两组出血、深静脉血栓及热诱导血栓事件率均低且相近。抗凝不应视为有症状静脉反流腔内热消融的禁忌证。

要点

  • 华法林抗凝患者行大/小隐静脉射频或激光消融的1年持续消融率达96%,与对照99%相当。
  • 抗凝组与对照组深静脉血栓率分别为1%与1.6%,热诱导血栓率分别为1%与0.8%。
  • 仅1例抗凝患者拔除静脉属支出血,加压控制,抗凝并非热消融禁忌。

核心结论

  • 华法林抗凝患者行大/小隐静脉射频或激光消融的持久性、安全性和疗效与未抗凝对照相当。
  • 抗凝不应被视为有症状静脉反流行大/小隐静脉腔内热消融的禁忌证。

研究设计与样本

  • 单中心回顾性研究,纳入接受华法林抗凝并接受射频或激光消融的患者,并与连续未抗凝对照比较。
  • 抗凝组65例患者共100例手术,对照组89例患者共127例手术,平均随访467天。

主要发现

  • 1年靶血管持续消融率抗凝组96%、对照组99%;18个月分别为92%与95%(P = .96)。
  • 持续消融率按治疗血管(P = .28)、射频与激光(P = .36)及抗血小板治疗(P = .92)比较均无显著差异。
  • 抗凝组1例(1%)术后2天拔除静脉属支出血,加压控制;对照组无出血报告。
  • 抗凝组同侧深静脉血栓1/100(1%),对照组2/127(1.6%);热诱导血栓分别为1/100(1%)与1/127(0.8%)。

关键数值与推荐

  • 抗凝最常见指征为心房颤动(52%)、远期深静脉血栓(29%)和机械心脏瓣膜(8%)。
  • 手术构成:射频127例(56%)、激光100例(44%);大隐静脉或其属支189例(83%)、小隐静脉38例(17%)。
  • 抗凝组平均年龄67岁、男性51%、冠心病9%、高血压55%、从不吸烟86%;对照组分别为52岁、27%、0%、20%、69%。

临床怎么用

  • 对华法林抗凝且有症状性大/小隐静脉反流的患者,可考虑行射频或激光消融,不以抗凝作为禁忌。
  • 围术期应关注出血风险,尤其华法林超治疗范围时,但本研究显示严重出血罕见。
  • 术后需监测深静脉血栓及热诱导血栓,尽管本研究事件率低且与对照相近。

局限性

  • 单中心回顾性设计,抗凝组与对照组基线特征存在差异(年龄、性别、冠心病、高血压、吸烟史)。
  • 样本量有限,出血及血栓事件数少,组间比较统计效能不足。
  • 仅纳入华法林抗凝患者,结论不能直接外推至直接口服抗凝药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the efficacy, durability, and safety of radiofrequency ablation (RFA) and endovenous laser ablation (EVLA) of the great saphenous vein (GSV) and small saphenous vein (SSV) to treat symptomatic venous reflux in patients receiving therapeutic anticoagulation. METHODS: Patients treated at a single institution with RFA or EVLA while receiving warfarin (Coumadin) anticoagulation were identified retrospectively along with a consecutive sample of patients not receiving anticoagulation who were similarly treated. Patients' demographics, comorbidities, procedural details, and follow-up data were obtained from electronic medical records. Outcomes of interest included the rates of persistent vein ablation, bleeding, deep venous thrombosis (DVT), and endothermal heat-induced thrombosis. Groups were compared using χ2 tests, Fisher exact test, Kaplan-Meier curves, and Cox proportional hazard modeling. RESULTS: There were 100 procedures performed in 65 patients receiving anticoagulation and 127 procedures in 89 control patients. Mean follow-up time was 467 days. The most common indications for anticoagulation were atrial fibrillation (52%), remote DVT (29%), and mechanical heart valves (8%). Patients receiving anticoagulation were on average older (67 years vs 52 years), were more likely to be male (51% vs 27%), and had higher rates of coronary disease (9% vs 0%) and hypertension (55% vs 20%), although they were more likely to have never smoked (86% vs 69%). There were 127 RFA procedures (56%) and 100 EVLA procedures (44%); 189 procedures treated the GSV or its tributaries (83%), and 38 treated the SSV (17%). At 1 year, the target vessel remained ablated after 96% of procedures performed with anticoagulation and in 99% of controls; at 18 months, rates were 92% vs 95% (P = .96). Rates of persistent ablation did not differ significantly by vessel treated (P = .28), EVLA vs RFA (P = .36), or use of antiplatelet therapy (P = .92). One patient had bleeding from a phlebectomy site 2 days postprocedurally when supratherapeutic on warfarin; this was controlled with pressure. DVT in the ipsilateral leg occurred within 90 days after 1 of 100 (1%) procedures in patients receiving anticoagulation and 2 of 127 (1.6%) procedures in control patients; endothermal heat-induced thrombosis rates were similarly 1 of 100 (1%) procedures in patients receiving anticoagulation and 1 of 127 (0.8%) in control patients. CONCLUSIONS: This is the largest series to date reporting >30-day follow-up for patients undergoing venous ablation procedures while receiving anticoagulation and the longest follow-up reported of any series. Durability, safety, and efficacy of vein ablation in patients receiving anticoagulation are comparable to those in control patients. Anticoagulation should not be considered a contraindication to endothermal ablation of the GSV or SSV for symptomatic venous reflux.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Westin GG, Cayne NS, Lee V, et al. Radiofrequency and laser vein ablation for patients receiving warfarin anticoagulation is safe, effective, and durable. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 31987758. doi:10.1016/j.jvsv.2019.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。